Natixis Sage Therapeutics, Inc. Transaction History
Natixis
- $19.1 Billion
- Q1 2024
A detailed history of Natixis transactions in Sage Therapeutics, Inc. stock. As of the latest transaction made, Natixis holds 95 shares of SAGE stock, worth $1,024. This represents 0.0% of its overall portfolio holdings.
Number of Shares
95
Previous 31,000
99.69%
Holding current value
$1,024
Previous $671,000
99.85%
% of portfolio
0.0%
Previous 0.0%
Shares
5 transactions
Others Institutions Holding SAGE
# of Institutions
222Shares Held
52.7MCall Options Held
207KPut Options Held
191K-
Vanguard Group Inc Valley Forge, PA5.75MShares$62 Million0.0% of portfolio
-
Rtw Investments, LP New York, NY5.48MShares$59.1 Million1.65% of portfolio
-
Black Rock Inc. New York, NY4.89MShares$52.7 Million0.0% of portfolio
-
Wellington Management Group LLP Boston, MA4.75MShares$51.2 Million0.02% of portfolio
-
State Street Corp Boston, MA4.49MShares$48.5 Million0.0% of portfolio
About Sage Therapeutics, Inc.
- Ticker SAGE
- Exchange NASDAQ
- Sector Healthcare
- Industry Biotechnology
- Shares Outstandng 59,422,300
- Market Cap $641M
- Description
- Sage Therapeutics, Inc., a biopharmaceutical company, develops and commercializes medicines to treat central nervous system disorders. Its lead product candidate is ZULRESSO, an intravenous formulation of brexanolone for the treatment of postpartum depression (PPD) in adults. The company's product pipeline also includes zuranolone, a neuroactive...